In our dataset, all 3 patients with MDM2 alterations had amplifications, consistent with amplification being the most frequent alteration type involving MDM2 in bladder cancer, which leads to a reduction or loss of function of p53 (36, 37). Here, TP53 is linked to urinary bladder cancer.